Press release
IonGate automates active substance research on transporters with SURFE2R Workstation
Frankfurt/Main (Germany), 31st July 2007. IonGate Biosciences GmbH announces the market launch of SURFE2R Workstation. For the first time a workstation allows a highly automated and efficient drug research on transporters and ion channels.With this SURFE2R Workstation, IonGate provides the next automated device generation after SURFE2R One and the first to measure 96 sensor array plates. It is especially conceived for applications with higher throughput in pharmaceutical drug screening. Robust and sensitive analytic methods enable the screening of defined compound libraries and the secondary screening of promising substances with high data quality.
The SURFE2R Technology (SURFace Electrogenic Event Reader) permits the direct functional characterization of transporters. This technique also offers a higher data quality than fluorescence-based assays and is substantially simpler and more efficient compared to radioactive methods. Core of the technology is a special biosensor developed by IonGate which measures the activity of transporters through electric charges with a reproducibly high quality.
Transporters, amongst others, play a fundamental role in information processing and the metabolism of any organism. In addition, they also influence the bioavail¬ability of drugs. With the SURFE2R Technology, IonGate offers comprehensive lab automation that is now paving the way to investigate this important new target class fast and economically.
Internationally IonGate will introduce its SURFE2R Workstation at the Drug Discovery & Development of Innovative Therapeutics (DDT) from the 6th to the 9th of August 2007 in Boston, USA and showcases its efficiency with a demonstration model at booth no. 513.
Photo available up on request: info@iongate.net
Contact
Wolfgang Lerch
Managing Director
IonGate Biosciences GmbH
Industriepark Hoechst / Building D528
65926 Frankfurt/Main
Germany
phone +49.69.305.85 400
fax +49.69.305.85 444
email info@iongate.net
Dr. Carsten Haber
Scientific Consultant US
IonGate Biosciences GmbH
49 Oak Street
Cohasset, MA 02025
USA
phone +1.781.923.19 61
cell +1.617.794.99 21
email info@iongate.net
Media inquiries
Dr. Holger Bengs
Biotech Consulting
phone +49.69.619.94 273
fax +49.69.619.94 249
email info@holgerbengs.de
About IonGate Biosciences GmbH
IonGate Biosciences GmbH develops, produces and markets innovative screening technologies to investigate transporters and is the worldwide leading company in this area.
Transporters are essential for the metabolic functions of the cell, information proc¬essing in the entire organism and play a fundamental role to the health of humans. Due to their difficult experimental accessibility transporters are underrepresented in current drug screening processes so far. For the first time IonGate provides with SURFE2R One and SURFE2R Workstation a highly precise functional screening of transporters in higher throughput and thereby positions itself as a strong partner for the pharmaceutical industry. With its SURFE2R Workstation IonGate has created a technological basis for an automated and robust analytical technique. The company supplies complete solutions, besides disposables and reagents, this mainly com¬prises individual consulting services comprising the design of customized applica¬tions.
IonGate Biosciences GmbH is a venture capital financed biotechnology company located in Frankfurt/Main in Germany. In addition to the main financier and leading partner Heidelberg Innovation the KfW holds a stake in IonGate. The company was established in 2000 and currently employs more than 30 staff members.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IonGate automates active substance research on transporters with SURFE2R Workstation here
News-ID: 25000 • Views: …
More Releases from Dr. Holger Bengs Biotech Consulting
IonGate starts commercialization of SURFE2R in Asia
Frankfurt/Main, Germany, March 12, 2008. IonGate Biosciences is expanding its operations to market the SURFE2R (SURFace Electrogenic Event Reader) Technology to the Japanese market. BRC - Bio Research Center Co. Ltd Nagoya, Japan and IonGate jointly introduce the proprietary technique to automatically screen transport proteins in high throughput at meetings in Japan, thus making the technology accessible to the Asian market.
BRC is an established partner able to supply Japan’s researchers…
IonGate presents SURFE2R Technology and relevant fields of application at Biophy …
Frankfurt/Main (Germany), January 28, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins at the 52nd Annual Meeting and 16th International Biophysics Congress. The joint meeting of the American Biophysical Society takes place in Long Beach, California, USA, on February 2 – 6, 2008. Scientists from industry, universities and private academic institutes use this opportunity to present results of their latest research…
IonGate completes third funding round and expands its business to the USA
Frankfurt/Main (Germany), 16th January 2008. IonGate Biosciences GmbH announces the closing of the third funding round. The capital contribution of the investors Heidelberg Innovation and KfW (Kreditanstalt für Wiederaufbau) therewith amounts to €4.6 million in 2007. IonGate will use the increase in capital to expand its international business activities, for the worldwide commercialization of the SURFE2R Technology (SURFace Electrogenic Event Reader) and for the further development of the SURFE2R Workstation.
In…
Protagen raises €1 million to expand its protein biochips business unit
Dortmund, Germany and New Jersey, USA, 15 January 2008: Protagen AG, a leading provider of products, services and software solutions for protein research, announces the closing of an interim financing round. The €1 million raised will be used to expand the company’s protein biochips business unit.
The capital raised in this round has come from the existing institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and S-Venture Capital Dortmund…
More Releases for IonGate
IonGate at the SBS Symposium Europe in Dresden
Frankfurt/Main (Germany), 6th June 2008. IonGate Biosciences GmbH will present relevant application fields for the proprietary SURFE2R Technology (SURFace Electrogenic Event Reader) at the SBS Symposium “Label Free Technologies in Drug Discovery” in Dresden, Germany. The meeting is being held at the international congress center on June 10 – 11.
Dr. Henning Vollert will explain the advantages of the cell- and label-free technology in comparison to the more conventional patch clamp…
IonGate hosts workshop and presents new SURFE2R prototype at SBS 2008
Frankfurt/Main (Germany), March 31, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins in a workshop at the SBS 2008, 14th Annual Conference & Exhibition of the Society of Biomolecular Sciences. The meeting takes place in St. Louis, Missouri, USA, on April 6 – 10, 2008. Additionally IonGate will give an exclusive preview of the prototype for the new SURFE2R Workstation 5000.
Immediately…
IonGate starts commercialization of SURFE2R in Asia
Frankfurt/Main, Germany, March 12, 2008. IonGate Biosciences is expanding its operations to market the SURFE2R (SURFace Electrogenic Event Reader) Technology to the Japanese market. BRC - Bio Research Center Co. Ltd Nagoya, Japan and IonGate jointly introduce the proprietary technique to automatically screen transport proteins in high throughput at meetings in Japan, thus making the technology accessible to the Asian market.
BRC is an established partner able to supply Japan’s researchers…
IonGate presents SURFE2R Technology and relevant fields of application at Biophy …
Frankfurt/Main (Germany), January 28, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins at the 52nd Annual Meeting and 16th International Biophysics Congress. The joint meeting of the American Biophysical Society takes place in Long Beach, California, USA, on February 2 – 6, 2008. Scientists from industry, universities and private academic institutes use this opportunity to present results of their latest research…
IonGate completes third funding round and expands its business to the USA
Frankfurt/Main (Germany), 16th January 2008. IonGate Biosciences GmbH announces the closing of the third funding round. The capital contribution of the investors Heidelberg Innovation and KfW (Kreditanstalt für Wiederaufbau) therewith amounts to €4.6 million in 2007. IonGate will use the increase in capital to expand its international business activities, for the worldwide commercialization of the SURFE2R Technology (SURFace Electrogenic Event Reader) and for the further development of the SURFE2R Workstation.
In…
IonGate wins the Contest “365 Landmarks in the Land of Ideas”
Frankfurt/Main (Germany), 26th November 2007. IonGate Biosciences GmbH was elected by the initiative “Germany - Land of Ideas” as landmark in 2008. The motto “Surfing into the world of drugs” received the jury’s acclaim. IonGate will open it\'s doors to the public on November 17th 2008 and celebrate the award with an open day, offering visitors the rare opportunity to explore a highly innovative biotech company. A comprehensible program will…
